

Daniel H Solomon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1534155/publications.pdf>

Version: 2024-02-01

265
papers

17,736
citations

13827

67
h-index

15683

125
g-index

279
all docs

279
docs citations

279
times ranked

18504
citing authors

#	ARTICLE	IF	CITATIONS
1	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
2	Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis. <i>Circulation</i> , 2003, 107, 1303-1307.	1.6	1,117
3	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019, 380, 752-762.	13.9	886
4	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , 2016, 375, 2519-2529.	13.9	607
5	Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults. <i>Circulation</i> , 2004, 109, 2068-2073.	1.6	493
6	Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. <i>American Heart Journal</i> , 2004, 148, 99-104.	1.2	489
7	Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. <i>Arthritis and Rheumatism</i> , 2002, 47, 434-444.	6.7	446
8	The Comparative Safety of Analgesics in Older Adults With Arthritis. <i>Archives of Internal Medicine</i> , 2010, 170, 1968.	4.3	348
9	Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2525.	3.8	332
10	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 576-582.	0.5	304
11	Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable. <i>Epidemiology</i> , 2006, 17, 268-275.	1.2	299
12	Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1929-1937.	3.1	287
13	Compliance With Osteoporosis Medications. <i>Archives of Internal Medicine</i> , 2005, 165, 2414.	4.3	284
14	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1920-1925.	0.5	255
15	Active-comparator design and new-user design in observational studies. <i>Nature Reviews Rheumatology</i> , 2015, 11, 437-441.	3.5	225
16	Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population-Based Survey. <i>Arthritis Care and Research</i> , 2016, 68, 574-580.	1.5	221
17	The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults. <i>Archives of Internal Medicine</i> , 2010, 170, 1979.	4.3	212
18	Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2002, 162, 1099.	4.3	199

#	ARTICLE	IF	CITATIONS
19	Cardiovascular risk factors in women with and without rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 3444-3449.	6.7	191
20	Opioid Analgesics and the Risk of Fractures in Older Adults with Arthritis. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 430-438.	1.3	176
21	Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. <i>Arthritis and Rheumatism</i> , 2006, 54, 1378-1389.	6.7	166
22	Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3790-3798.	6.7	166
23	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1154-1164.	2.9	160
24	Relationship Between COX-2 Specific Inhibitors and Hypertension. <i>Hypertension</i> , 2004, 44, 140-145.	1.3	148
25	Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 45-52.	0.9	148
26	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 456-464.	0.5	139
27	Nonoccupational risk factors for carpal tunnel syndrome. <i>Journal of General Internal Medicine</i> , 1999, 14, 310-314.	1.3	132
28	Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?. <i>Arthritis and Rheumatology</i> , 2014, 66, 775-782.	2.9	131
29	Trends in Prescription of Opioids From 2003 to 2009 in Persons With Knee Osteoarthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1489-1495.	1.5	127
30	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	3.1	127
31	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
32	Underuse of osteoporosis medications in elderly patients with fractures. <i>American Journal of Medicine</i> , 2003, 115, 398-400.	0.6	123
33	Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: Rates and predictors of care in an academic rheumatology practice. <i>Arthritis and Rheumatism</i> , 2002, 46, 3136-3142.	6.7	118
34	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1674-1679.	0.5	113
35	Digital health technologies: opportunities and challenges in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 525-535.	3.5	109
36	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1360-1367.	0.5	108

#	ARTICLE	IF	CITATIONS
37	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Circulation</i> , 2018, 138, 1116-1126.	1.6	108
38	Risk of fractures in older adults using antihypertensive medications. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1561-1567.	3.1	106
39	Multimorbidity and rheumatic conditions"enhancing the concept of comorbidity. <i>Nature Reviews Rheumatology</i> , 2014, 10, 252-256.	3.5	103
40	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.5	100
41	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 489-497.	1.6	99
42	Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women , , . <i>American Journal of Clinical Nutrition</i> , 2014, 100, 959-967.	2.2	98
43	Adherence with osteoporosis practice guidelines: A multilevel analysis of patient, physician, and practice setting characteristics. <i>American Journal of Medicine</i> , 2004, 117, 919-924.	0.6	97
44	Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1712-1721.	1.5	96
45	Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-Î± Blockade with Nonbiologic DMARDs. <i>American Journal of Medicine</i> , 2013, 126, 730.e9-730.e17.	0.6	94
46	Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0122646.	1.1	94
47	Osteoporosis Telephonic Intervention to Improve Medication Regimen Adherence. <i>Archives of Internal Medicine</i> , 2012, 172, 477.	4.3	93
48	The Potential Economic Benefits of Improved Postfracture Care: A Cost-Effectiveness Analysis of a Fracture Liaison Service in the US Health-Care System. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1667-1674.	3.1	90
49	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1536-1540.	3.1	90
50	The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. <i>American Journal of Medicine</i> , 2017, 130, 1415-1422.e4.	0.6	87
51	Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. <i>Arthritis and Rheumatism</i> , 2008, 59, 1097-1104.	6.7	86
52	A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2792-2798.	1.8	86
53	Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus) Tj ETQq1 1 0.784314 rgBT /Overload 1.0 86 38, 3282-3292.	1.0	86
54	Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. <i>Rheumatology</i> , 2011, 50, 40-46.	0.9	85

#	ARTICLE	IF	CITATIONS
55	Lipid levels and bone mineral density. <i>American Journal of Medicine</i> , 2005, 118, 1414.e1-1414.e5.	0.6	84
56	Effects of Interleukin-1 β Inhibition on Incident Hip and Knee Replacement. <i>Annals of Internal Medicine</i> , 2020, 173, 509-515.	2.0	84
57	Selective cyclooxygenase 2 inhibitors and cardiovascular events. <i>Arthritis and Rheumatism</i> , 2005, 52, 1968-1978.	6.7	83
58	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3390-3398.	6.7	83
59	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1968-1975.	0.5	82
60	Contribution of hospital characteristics to the volume-outcome relationship: Dislocation and infection following total hip replacement surgery. <i>Arthritis and Rheumatism</i> , 2002, 46, 2436-2444.	6.7	79
61	Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?. <i>American Journal of Medicine</i> , 2003, 115, 715-720.	0.6	78
62	Medication Use Patterns for Osteoporosis: An Assessment of Guidelines, Treatment Rates, and Quality Improvement Interventions. <i>Mayo Clinic Proceedings</i> , 2005, 80, 194-202.	1.4	78
63	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 653.e7-653.e16.	0.6	75
64	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084.	0.9	74
65	Relationship of Interleukin-1 β Blockade With Incident Gout and Serum Uric Acid Levels. <i>Annals of Internal Medicine</i> , 2018, 169, 535.	2.0	74
66	Improving Care of Patients At-Risk for Osteoporosis: A Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2007, 22, 362-367.	1.3	73
67	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	1.5	73
68	Does self-management education benefit all populations with arthritis? A randomized controlled trial in a primary care physician network. <i>Journal of Rheumatology</i> , 2002, 29, 362-8.	1.0	73
69	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. <i>JAMA Internal Medicine</i> , 2018, 178, 1182.	2.6	71
70	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1823-1831.	2.9	70
71	Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. <i>Journal of the American College of Cardiology</i> , 2018, 71, 994-1004.	1.2	69
72	Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 232-239.	3.1	66

#	ARTICLE	IF	CITATIONS
73	Linkage of a Deidentified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research. <i>Arthritis Care and Research</i> , 2014, 66, 1790-1798.	1.5	65
74	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017, 69, 387-397.	2.9	65
75	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 430-436.	0.5	61
76	Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: A randomized controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 51, 383-387.	6.7	60
77	Osteoporosis treatments and adverse events. <i>Current Opinion in Rheumatology</i> , 2009, 21, 363-368.	2.0	59
78	Effect of Hydroxychloroquine on Insulin Sensitivity and Lipid Parameters in Rheumatoid Arthritis Patients Without Diabetes Mellitus: A Randomized, Blinded Crossover Trial. <i>Arthritis Care and Research</i> , 2014, 66, 1246-1251.	1.5	58
79	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	1.6	58
80	Medical Care Costs Associated With Rheumatoid Arthritis in the <sc>US</sc>: A Systematic Literature Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 1431-1438.	1.5	58
81	The contribution of obesity to prescription opioid use in the United States. <i>Pain</i> , 2019, 160, 2255-2262.	2.0	58
82	Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. <i>Arthritis Research and Therapy</i> , 2008, 10, R95.	1.6	57
83	The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1624-1631.	6.7	57
84	Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non-Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 2004-2010.	2.9	57
85	Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 205-213.	1.6	55
86	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1753-1765.	1.8	55
87	Prescription opioid use among older adults with arthritis or low back pain. <i>Arthritis and Rheumatism</i> , 2006, 55, 35-41.	6.7	54
88	Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. <i>Arthritis Care and Research</i> , 2012, 64, 184-189.	1.5	54
89	Statin Therapy and Risk of Fracture. <i>JAMA Internal Medicine</i> , 2015, 175, 171.	2.6	53
90	Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry. <i>Journal of Rheumatology</i> , 2014, 41, 227-234.	1.0	52

#	ARTICLE	IF	CITATIONS
91	The "Infectious" of COVID-19. <i>Arthritis and Rheumatology</i> , 2020, 72, 1806-1808.	2.9	52
92	Osteoporosis Improvement: A Large-Scale Randomized Controlled Trial of Patient and Primary Care Physician Education. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1808-1815.	3.1	51
93	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1813-1818.	0.5	50
94	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1920-1925.	1.5	49
95	Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors. <i>Arthritis and Rheumatology</i> , 2019, 71, 670-677.	2.9	49
96	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. <i>JAMA Network Open</i> , 2019, 2, e198061.	2.8	48
97	Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , 2019, 58, 1746-1754.	0.9	44
98	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 222-228.	1.6	42
99	Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1150-1155.	0.5	41
100	Statin lipid-lowering drugs and bone mineral density. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 219-226.	0.9	40
101	Risk of incident atrial fibrillation in gout: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1473-1478.	0.5	40
102	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1374-1380.	2.9	40
103	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 1099-1104.	1.0	39
104	The risk of infection associated with tumor necrosis factor $\hat{\pm}$ antagonists: Making sense of epidemiologic evidence. <i>Arthritis and Rheumatism</i> , 2008, 58, 919-928.	6.7	38
105	New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 560-563.	0.9	37
106	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 399-405.	1.6	37
107	Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis?: A cost-effectiveness analysis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1967-1975.	6.7	35
108	Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1741-1751.	1.2	35

#	ARTICLE	IF	CITATIONS
109	Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 108-112.	0.9	34
110	Instrumental Variable Analysis of Secondary Pharmacoepidemiologic Data. <i>Epidemiology</i> , 2006, 17, 373-374.	1.2	33
111	Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1989-1996.	1.0	33
112	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 537-546.	2.9	33
113	Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. <i>RMD Open</i> , 2018, 4, e000593.	1.8	33
114	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0210459.	1.1	31
115	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	1.0	31
116	Roles of Nurse Practitioners and Physician Assistants in Rheumatology Practices in the US. <i>Arthritis Care and Research</i> , 2014, 66, 1108-1113.	1.5	30
117	Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs. <i>American Journal of Medicine</i> , 2015, 128, 539.e7-539.e17.	0.6	30
118	Trends in Knee Magnetic Resonance Imaging. <i>Medical Care</i> , 2003, 41, 687-692.	1.1	29
119	Agreement between patient report and medical record review for medications used for rheumatoid arthritis: The accuracy of self-reported medication information in patient registries. <i>Arthritis and Rheumatism</i> , 2007, 57, 234-239.	6.7	29
120	Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. <i>Arthritis and Rheumatism</i> , 2006, 55, 873-877.	6.7	28
121	Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 777-786.	0.9	28
122	Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5611-5620.	1.8	28
123	Development of a preliminary index that predicts adverse events after total knee replacement. <i>Arthritis and Rheumatism</i> , 2006, 54, 1536-1542.	6.7	27
124	Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 1419-1424.	1.5	27
125	The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. <i>Journal of Rheumatology</i> , 2003, 30, 792-8.	1.0	27
126	Performance of Matrixâ€­Based Risk Models for Rapid Radiographic Progression in a Cohort of Patients With Established Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 526-533.	1.5	26

#	ARTICLE	IF	CITATIONS
127	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 133-142.	1.6	26
128	Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 801-806.	1.5	26
129	Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. <i>Rheumatology</i> , 2018, 57, 1933-1937.	0.9	26
130	Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 712-721.	2.9	26
131	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1435-1444.	1.8	26
132	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 2065-2071.	2.9	26
133	Fibromyalgia: Scourge of humankind or bane of a rheumatologist's existence?. <i>Arthritis and Rheumatism</i> , 1997, 40, 1553-1555.	6.7	25
134	Development and validation of a patient satisfaction scale for musculoskeletal care. <i>Arthritis and Rheumatism</i> , 1999, 12, 96-100.	6.7	25
135	Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. <i>Rheumatology</i> , 2016, 55, 286-290.	0.9	25
136	Gout and the Risk of Non-vertebral Fracture. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 230-236.	3.1	25
137	Incorporating natural language processing to improve classification of axial spondyloarthritis using electronic health records. <i>Rheumatology</i> , 2020, 59, 1059-1065.	0.9	25
138	Comparison of Care Provided in Practices With Nurse Practitioners and Physician Assistants Versus Subspecialist Physicians Only: A Cohort Study of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1664-1670.	1.5	24
139	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	2.9	24
140	Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. <i>Arthritis Research and Therapy</i> , 2016, 18, 280.	1.6	23
141	Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study. <i>Arthritis Care and Research</i> , 2019, 71, 903-913.	1.5	23
142	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. <i>Rheumatology</i> , 2019, 58, 2025-2030.	0.9	23
143	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidence-Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1675-1683.	6.7	22
144	Cardiovascular care and cancer screening in female nurses with and without rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 429-432.	6.7	21

#	ARTICLE	IF	CITATIONS
145	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816.	0.9	21
146	Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting. <i>Arthritis Care and Research</i> , 2016, 68, 629-637.	1.5	20
147	Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial. <i>Journal of Rheumatology</i> , 2016, 43, 38-45.	1.0	20
148	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2106-2113.	2.9	19
149	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	0.9	19
150	A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. <i>Rheumatology</i> , 2020, 59, 900-903.	0.9	19
151	Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1421-1429.	2.9	19
152	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , 2015, 30, 1633-1638.	1.3	18
153	Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 81-87.	1.6	18
154	Association between inflammation and systolic blood pressure in RA compared to patients without RA. <i>Arthritis Research and Therapy</i> , 2018, 20, 107.	1.6	18
155	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 840-846.	1.6	18
156	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	0.9	18
157	The Comparative Safety and Effectiveness of TNF-alpha Antagonists. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 7-18.	2.2	17
158	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1755.	3.8	17
159	Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	16
160	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 495-504.	0.9	16
161	Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials. <i>Rheumatology</i> , 2020, 59, 709-717.	0.9	16
162	Osteoporosis action: design of the healthy bones project trial. <i>Contemporary Clinical Trials</i> , 2005, 26, 78-94.	0.8	15

#	ARTICLE	IF	CITATIONS
163	<i>TRAF1/C5</i> but Not<i>PTPRC</i> Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	15
164	Validation of claimsâ€based algorithms for gout flares. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 820-826.	0.9	15
165	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and Ninja Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	1.0	14
166	Challenges in Implementing Treat-to-Target Strategies in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 101-112.	0.8	14
167	Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 883-890.	0.5	14
168	Classifying Pseudogout Using Machine Learning Approaches With Electronic Health Record Data. <i>Arthritis Care and Research</i> , 2021, 73, 442-448.	1.5	14
169	Predictors of Stopping and Starting Diseaseâ€Modifying Antirheumatic Drugs for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1152-1158.	1.5	13
170	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , 2015, 17, 83.	1.6	13
171	Impact of Changes in Inflammation on Estimated Tenâ€Year Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1392-1398.	2.9	13
172	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with threeâ€group matching weights. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 182-190.	0.9	13
173	Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. <i>Journal of Rheumatology</i> , 2021, 48, 1364-1370.	1.0	13
174	Uptake of the First Biosimilar Infliximab since its Approval in South Korea. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	2.9	12
175	Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. <i>Clinical Rheumatology</i> , 2015, 34, 1697-1704.	1.0	12
176	Participation in Clinical Research Registries: A Focus Group Study Examining Views From Patients With Arthritis and Other Chronic Illnesses. <i>Arthritis Care and Research</i> , 2016, 68, 974-980.	1.5	12
177	Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. <i>RMD Open</i> , 2018, 4, e000771.	1.8	12
178	Prevalence and predictors for sustained remission in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0214981.	1.1	12
179	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 1359-1365.	1.0	12
180	Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients With Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2022, 4, 3-7.	0.9	12

#	ARTICLE	IF	CITATIONS
181	Which Patients With Knee Problems Are Likely to Benefit From Nonarthroplasty Surgery?. Archives of Internal Medicine, 2004, 164, 509.	4.3	11
182	Benefits and Sustainability of a Learning Collaborative for Implementation of Treatâ€”Target in Rheumatoid Arthritis: Results of a Clusterâ€”Randomized Controlled Phase <scp>II</scp> Clinical Trial. Arthritis Care and Research, 2018, 70, 1551-1556.	1.5	11
183	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. PLoS ONE, 2018, 13, e0200886.	1.1	11
184	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1225-1231.	2.9	11
185	Is race or ethnicity associated with underâ€”utilization of statins among women in the United States: The study of women's health across the nation. Clinical Cardiology, 2020, 43, 1388-1397.	0.7	11
186	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	1.2	11
187	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3197-3207.	3.0	11
188	Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. Journal of Clinical Epidemiology, 2002, 55, 121-128.	2.4	10
189	Pharmacoepidemiology and rheumatic diseases: 2001â€”2002. Current Opinion in Rheumatology, 2003, 15, 122-126.	2.0	10
190	Outcomes of lupus and rheumatoid arthritis patients with primary dengue infection: A seven-year report from Brazil. Seminars in Arthritis and Rheumatism, 2018, 47, 749-755.	1.6	10
191	Treatâ€”Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial. Arthritis Care and Research, 2021, 73, 207-214.	1.5	10
192	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. Journal of Rheumatology, 2014, 41, 2370-2378.	1.0	9
193	Lowâ€”Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Metaâ€”Analysis of Randomized Controlled Trials. Arthritis Care and Research, 2020, 72, 1140-1146.	1.5	9
194	Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine. Annals of the Rheumatic Diseases, 2022, 81, 1045-1048.	0.5	9
195	Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Research and Therapy, 2016, 18, 94.	1.6	8
196	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMC Dermatology, 2017, 17, 11.	2.1	8
197	Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence. Journal of Rheumatology, 2020, 47, 1261-1266.	1.0	8
198	Physician Prescribing Patterns and Risk of Future Longâ€”Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. Arthritis and Rheumatology, 2020, 72, 1082-1090.	2.9	8

#	ARTICLE	IF	CITATIONS
199	Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. <i>ACR Open Rheumatology</i> , 2021, 3, 371-380.	0.9	8
200	Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 1036-1045.	1.5	8
201	Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. <i>BMC Medical Research Methodology</i> , 2017, 17, 59.	1.4	7
202	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. <i>ACR Open Rheumatology</i> , 2019, 1, 552-559.	0.9	7
203	Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development. <i>ACR Open Rheumatology</i> , 2020, 2, 65-73.	0.9	7
204	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. <i>Arthritis Research and Therapy</i> , 2021, 23, 26.	1.6	7
205	Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1323-1329.	0.5	7
206	Mechanistic Insights Into the Link Between Inflammation and Cardiovascular Disease. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 575-577.	1.3	6
207	Rheumatoid arthritis quality measures and radiographic progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 9-13.	1.6	6
208	The Implications of the Sequestosome 1 Mutation P392L in Patients with Paget's Disease in a United States Cohort. <i>Calcified Tissue International</i> , 2016, 98, 489-496.	1.5	6
209	Pain Severity in Relation to the Final Menstrual Period in a Prospective Multiethnic Observational Cohort: Results From the Study of Women's Health Across the Nation. <i>Journal of Pain</i> , 2017, 18, 178-187.	0.7	6
210	Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women's Health Across the Nation (SWAN). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
211	Pseudogout among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease. <i>Rheumatology International</i> , 2018, 38, 1083-1088.	1.5	6
212	Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. <i>BMC Rheumatology</i> , 2018, 2, 17.	0.6	6
213	Temporal increases in 25-hydroxyvitamin D in midlife women: Longitudinal results from the Study of Women's Health Across the Nation. <i>Clinical Endocrinology</i> , 2019, 91, 48-57.	1.2	6
214	Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease: A Nationwide Study of Veterans. <i>Arthritis Care and Research</i> , 2023, 75, 277-282.	1.5	6
215	Factors Associated With 10-Year Declines in Physical Health and Function Among Women During Midlife. <i>JAMA Network Open</i> , 2022, 5, e2142773.	2.8	6
216	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 177.	1.6	5

#	ARTICLE	IF	CITATIONS
217	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 04, 179.	1.5	5
218	Percutaneous Vertebroplasty Among Low Income Medicare Beneficiaries. <i>Spine</i> , 2007, 32, 2910-2914.	1.0	4
219	Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. <i>Arthritis and Rheumatology</i> , 2016, 68, 332-336.	2.9	4
220	Medication Use by Race and Ethnicity in Women Transitioning Through the Menopause: A Study of Women's Health Across the Nation Drug Epidemiology Study. <i>Journal of Women's Health</i> , 2016, 25, 599-605.	1.5	4
221	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. <i>PLoS ONE</i> , 2018, 13, e0192788.	1.1	4
222	Sleep medications and sleep disturbances across middle aged pre- or peri-menopausal women of different race and ethnicities: A SWAN pharmacoepidemiology cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1715-1721.	0.9	4
223	Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e045074.	0.8	4
224	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. <i>Rheumatology</i> , 2018, 57, 1364-1369.	0.9	3
225	Editorial: Tumor Necrosis Factor Antagonists: Killing Two Birds With One Biologic Stone. <i>Arthritis and Rheumatology</i> , 2018, 70, 326-329.	2.9	3
226	Comment on: Comorbidity burden in axial spondyloarthritis: a cluster analysis: reply. <i>Rheumatology</i> , 2020, 59, 692-693.	0.9	3
227	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 173, 167.	2.0	3
228	Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel. <i>ACR Open Rheumatology</i> , 2021, 3, 341-348.	0.9	3
229	Confirming Prior and Identifying Novel Correlates of Acute Calcium Pyrophosphate Crystal Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 283-288.	1.5	3
230	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , 2021, 60, 2963-2968.	0.9	3
231	Exploring patient experiences coping with using multiple medications: a qualitative interview study. <i>BMJ Open</i> , 2021, 11, e046860.	0.8	3
232	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3
233	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , 2017, 19, 130.	1.6	2
234	Blood pressure lowering medication initiation and fracture risk: a SWAN pharmacoepidemiology study. <i>Archives of Osteoporosis</i> , 2019, 14, 73.	1.0	2

#	ARTICLE	IF	CITATIONS
235	Adverse Events and Resource Use Before and After Treatâ€toâ€Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2019, 71, 1243-1248.	1.5	2
236	Medications for gout and its comorbidities: mutual benefits?. <i>Current Opinion in Rheumatology</i> , 2021, 33, 145-154.	2.0	2
237	A7.16â€...Lack of Replication of <i>PTPRC Gene</i> as a Predictor of Response to Anti-Tumour Necrosis Factor Therapy in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A53.2-A53.	0.5	1
238	Editorial: The Vital Role of Randomized Controlled Trials in <i>Arthritis & Rheumatology</i>. <i>Arthritis and Rheumatology</i> , 2015, 67, 2555-2556.	2.9	1
239	Potential confounding in colchicine and cardiovascular disease study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e27-e27.	0.5	1
240	Response to: â€Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?â€™ by Giannopoulos and Deftereos. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e29-e29.	0.5	1
241	Trust in Publication: Now More Than Ever. <i>Arthritis and Rheumatology</i> , 2019, 71, 1593-1594.	2.9	1
242	SAT0450â€...SENSITIVITY OF DUAL-ENERGY CT SCANNING, ULTRASOUND, AND X-RAY FOR CRYSTAL-PROVEN PSEUDOGOUT. , 2019, , .		1
243	THU0155â€...PATIENT ADHERENCE WITH A SMARTPHONE APP FOR DISEASE MONITORING IN RHEUMATOID ARTHRITIS. , 2019, , .		1
244	Education and Professional Development in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 155-166.	0.8	1
245	Development of a Medicare Claimsâ€Based Model to Predict Persistent Highâ€Dose Opioid Use After Total Knee Replacement. <i>Arthritis Care and Research</i> , 2022, 74, 1342-1348.	1.5	1
246	A Picture Is Worth a Thousand Words, But Only If It Is a Good Picture. <i>Arthritis and Rheumatology</i> , 2021, 73, 912-913.	2.9	1
247	Implementing a <sc>Treatâ€toâ€Target</sc> Approach for Rheumatoid Arthritis During the <sc>COVID</sc>â€19 Pandemic: Results of a Virtual Learning Collaborative Program. <i>Arthritis Care and Research</i> , 2022, 74, 572-578.	1.5	1
248	Quality improvement for rheumatoid arthritis care: results from a focus group. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 428-435.	0.4	1
249	User experience with a voice-enabled smartphone app to collect patient-reported outcomes in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
250	Determining the best treatments for the right people in rheumatology. <i>Current Opinion in Rheumatology</i> , 2008, 20, 121-122.	2.0	0
251	Clinical research in rheumatology: many promises and several disappointments. <i>Current Opinion in Rheumatology</i> , 2009, 21, 93-94.	2.0	0
252	Dr. Yoshida, <i>et al</i> reply. <i>Journal of Rheumatology</i> , 2016, 43, 1253.2-1253.	1.0	0

#	ARTICLE	IF	CITATIONS
253	Reply. Arthritis and Rheumatology, 2018, 70, 476-476.	2.9	0
254	CS-11â€¦The effects of contextual sociodemographic factors and health resource concentration on hydroxychloroquine adherence among U.S. medicaid beneficiaries with lupus. , 2018, , .		0
255	O35â€¦Multimorbidity in patients with axial spondyloarthritis: a cluster analysis. Rheumatology, 2019, 58, .	0.9	0
256	Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Annals of Internal Medicine, 2019, 171, 578.	2.0	0
257	Reply to Letter to the Editor: â€œComparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Useâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2100-e2100.	1.8	0
258	Reply. Arthritis and Rheumatology, 2020, 72, 1407-1408.	2.9	0
259	Comment on: Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials: reply. Rheumatology, 2020, 59, e76-e76.	0.9	0
260	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Antiâ€¦Inflammatory Drug Users: Realâ€¦World Application. ACR Open Rheumatology, 2020, 2, 269-275.	0.9	0
261	<i>Arthritis & Rheumatology</i>: Evolving to Meet the Challenges of Rheumatology. Arthritis and Rheumatology, 2020, 72, 1254-1255.	2.9	0
262	Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1086-1087.	2.9	0
263	The relationship between 19â€¦year trends in medication use and changes in physical function among women in the midâ€¦life : A Study of Women 's Health Across the Nation pharmacoepidemiology study. Pharmacoepidemiology and Drug Safety, 2021, , .	0.9	0
264	Arthritis & Rheumatology: â€œ<sc>Midâ€¦Term</sc>â€¦Report. Arthritis and Rheumatology, 2022, 74, 1099-1101.	2.9	0
265	User experience with a voice-enabled smartphone app to collect patient-reported outcomes in rheumatoid arthritis.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0